On November 5, Dr. Fu Yuchen, Assistant to the Chairman of Shenzhen Cell Valley, and Sun Rui, Head of the Marketing Department, visited the Eye Hospital Affiliated with Wenzhou Medical University (WMU Eye Hospital) and engaged in in-depth discussions with the team of Professor Liang Yuanbo, Vice President of the hospital.

Guided by Director Tu Changsen of the International Medical Center, the Cell Valley delegation toured the hospital's history museum, minimally invasive surgical skills center, and national-level optometry clinic, gaining a systematic understanding of WMU Eye Hospital's integrated 'clinical-research-transformation' platform and its leading initiatives in myopia prevention, low-vision rehabilitation, and genetic retinal disease screening.

During the symposium, Sun Rui, Head of the Marketing Department, elaborated on the company's industrial-grade retroviral vector platform and CAR-T/NK cell preparation processes, with a special focus on the progress of the in-development project for glaucoma optic nerve protection. Professor Liang Yuanbo highly praised Cell Valley's innovations in ocular immune microenvironment regulation and cell therapy technology. He noted that blinding eye diseases such as glaucoma, uveitis, and genetic retinal disorders still lack definitive treatments, and immune cell therapies like CAR-NK hold promise for breaking through the limitations of traditional drugs and surgeries. Professor Liang also expressed strong interest in the company's recent clinical practices involving cell immunotherapy for patients domestically and internationally, highlighting its vast potential in ophthalmic diseases. Both parties agreed to explore deep collaboration in preclinical research, clinical trials, and technology translation to advance the application of cell therapy in ophthalmology.

The Eye Hospital Affiliated with Wenzhou Medical University, established in 1998, was approved in 2009 to additionally use the name 'Zhejiang Eye Hospital' by the provincial health department. In 2010, it opened its Hangzhou branch, becoming Zhejiang's first Class III Grade A ophthalmic specialty hospital. The hospital undertakes clinical, educational, research, and preventive healthcare missions and hosts national platforms such as the National Clinical Research Center for Ocular Diseases. Currently, it has developed a 'six-in-one' overall layout and a 'one body, two wings' strategic framework. With comprehensive specialties, it operates seven clinical centers, five medical technology departments, and five inpatient wards. Additionally, it has established a 'four-in-one' hierarchical diagnosis and treatment model within the hospital to address challenges like 'difficulty in accessing medical care and specialist consultations' for the public.